0
0
Acting CDC Director Jim O’Neill has called on vaccine manufacturers to develop separate measles, mumps, and rubella (MMR) vaccines, advocating for the replacement of the long-standing combination shot despite no published scientific evidence supporting such a change. This recommendation follows a recent advisory panel decision to split the MMR and varicella (chickenpox) vaccines for toddlers, moving away from the combined MMRV formulation.
Key Developments
Acting CDC Director Jim O’Neill, also deputy secretary of the U.S. Department of Health and Human Services (HHS), made the call on October 6, 2025, via a post on X, urging vaccine makers to create “safe monovalent vaccines” and to “break up the MMR shot into three completely separate shots”. His statement referenced a prior suggestion by President Donald Trump, who advocated for separating the MMR vaccine without providing scientific justification. O’Neill also endorsed the Advisory Committee on Immunization Practices (ACIP) recommendation to administer the chickenpox vaccine separately from the MMR vaccine for children around 12 months old, citing informed consent and parental choice.
Currently, there are no licensed monovalent vaccines for measles, mumps, or rubella in the United States. The MMR combination vaccine has been in use since 1971, designed to reduce the number of injections children receive and improve vaccination completion rates. The proposed shift would increase the number of required shots from two MMR doses to six individual injections if all three components were separated.
Expert Perspectives
Medical experts have expressed significant concern over the recommendation. Dr. Paul Offit, a vaccine expert at Children’s Hospital of Philadelphia and former member of the CDC’s vaccine advisory committee, stated that splitting the MMR vaccine would not improve safety and would instead “increase costs and decrease the likelihood of vaccination”. He emphasized that the idea has been thoroughly studied, particularly in response to the now-retracted 1998 study by Andrew Wakefield that falsely linked the MMR vaccine to autism, and no benefit was found.
Andrew Nixon, HHS communications director, claimed that standalone vaccines could “minimize the risk of side effects and enhance parental choice,” but provided no evidence to support this assertion. The CDC itself states on its website that “no published scientific evidence shows any benefit in separating the combination MMR vaccine into three individual shots” and that adverse reactions to combination vaccines are usually mild and comparable to those from separate vaccines.
Merck, manufacturer of one of the two approved MMR vaccines in the U.S., reiterated its commitment to the combination formulation, noting that using individual components would increase the number of injections and could lead to delayed or missed immunizations. GSK, producer of the other authorized MMR vaccine, highlighted that combination vaccines are essential for maintaining high vaccination coverage by simplifying the immunization process.
Public Health Implications
The MMR vaccine is 93% effective against measles, 72% effective against mumps, and 97% effective against rubella after one dose, with even higher protection following the recommended two doses. CDC guidelines continue to recommend two doses of measles-containing vaccine for children, starting at 12 to 15 months of age.
Public health officials warn that fragmenting the vaccine schedule could lead to lower completion rates. A 2017 study found that 69% of U.S. children completed the recommended series when receiving combination vaccines, compared to only 50% when parents opted for single-antigen vaccines. The American Academy of Pediatrics has cautioned that separating the MMR components would leave children vulnerable to serious diseases for longer periods.
The ACIP’s decision to split the MMR and varicella vaccines for the first dose was based on reducing the small risk of febrile seizures associated with the combined MMRV vaccine, though the risk remains low. The MMRV formulation will still be available as an option for the second dose, typically given at ages 4 to 6 years.
Limitations and Controversy
The push to separate the MMR vaccine lacks scientific foundation and appears politically influenced, given its alignment with President Trump’s previous statements on vaccines. The CDC has not provided data or clinical rationale to support the change, and no pharmaceutical company currently produces single-antigen measles, mumps, or rubella vaccines in the U.S..
Critics argue that the move undermines public confidence in vaccines and could reverse decades of progress in immunization policy. The timing coincides with the CDC’s shift from universal to individualized recommendations for COVID-19 vaccines, further emphasizing a policy of personal choice over population-level protection.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References:
